News

For years, pancreatic cancer has been considered immune to immunotherapy. Its tumors were “cold”—invisible to the body’s natural defenses and resistant to treatments that worked against other cancers. Patients had […]

For decades, pancreatic cancer has remained one of the most difficult cancers to treat. Too often diagnosed late and resistant to many standard therapies, it has long demanded new thinking, […]

UPDATE (5/12/2026): Following last week’s announcement of expanded access for daraxonrasib in pancreatic cancer, Revolution Medicines has now shared additional information and guidelines for physicians and patients interested in the […]

The Lustgarten Foundation’s annual International Women’s Day symposium, The Power of Persistence: Women Transforming Cancer Research and Care, highlights women’s critical role in advancing innovation in the fight against cancer. Co-chaired […]

We were disappointed to learn that the Galleri multi-cancer early detection (MCED) test, developed by GRAIL, did not meet the primary endpoint in its large randomized trial conducted in partnership […]

While cancer mortality rates in the United States have steadily declined over recent decades, a group of recalcitrant cancers remains stubbornly lethal. For diseases like pancreatic, ovarian, and upper GI […]

The American Cancer Society has released its Cancer Facts & Figures 2026—and for pancreatic cancer, the story is not one of progress. It is an alarm we can no longer […]

WHY EARLY DETECTION IN PANCREATIC CANCER CAN’T WAIT For decades, pancreatic cancer has been defined by late diagnosis and limited options. The disease often progresses silently and aggressively, with symptoms […]